Progentec uses a lab-based assay to detect lupus flares as early as 6-12 weeks before flares happen.
Oklahoma Medical Research Foundation has developed a highly effective and safe therapeutic for the treatment of glioblastoma. The compound, OKN-007, has the unique ability to cross the blood-brain barrier and has been successfully shown to decrease both tumor size and tumor vasculature in animal models of glioblastoma.
Drik is a pre clinical toxicology services laboratory for drug safety evaluation. They do preclinical screening tests for cosmetic industry and non clinical toxicology testing for chemical manufacturing.
Selexys Pharmaceuticals? pioneering work on the molecular mechanisms of inflammation has led to breakthroughs in novel therapeutics for inflammatory and thrombotic diseases and positioned Selexys with strong scientific underpinnings.
Hyalose, LLC is a biotechnology company focused on the commercialization of unique recombinant technologies for producing Hyaluronic Acid (HA), an important biomolecule for many healthcare and cosmetic applications.
Synereca Pharmaceuticals was created to address the growing problem of bacterial resistance to current antibiotics by developing orally active drugs that restore or increase the effectiveness of existing antibiotics.?
Otologic Pharmaceutics, Inc. (OP) is an Oklahoma-headquartered organization formed specifically to commercialize promising technologies that address novel pharmacological solutions for hearing and balanced health.
DormaTarg is a pharmaceutical company developing a series of small molecule oncology therapeutics that inhibit recurrence in metastasis prone cancers, with an initial focus on Triple Negative Breast Cancer.
EpimedX, LLC is an Oklahoma-based biotechnology company with the mission to develop Gene Regulation Therapy ? a promising technology that is expected to provide a safe, cost-effective and permanent treatment for sickle cell disease, beta-thalassemia and malaria without dangerous or harmful side effects.